Effects of remimazolam and propofol on sleep quality in patients undergoing gastrointestinal endoscopy

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200063114

Enrollment

Unknown

Registered

2022-08-31

Start date

2022-09-01

Completion date

Unknown

Last updated

2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep Disorders

Interventions

Remazolam group:The patient will be anesthetized by intravenous injection of remimazolam

Propofol group:The patient will be anesthetized by intravenous injection of propofol

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients scheduled for painless gastroenteroscopy. 2. Primary school education above grade 3, no dyslexia. 3. Patients with ASA Grade I to III. 4. Patients receiving propofol or Remazolam for painless gastroenteroscopy.

Exclusion criteria

Exclusion criteria: 1. Other surgeries and anesthesia were performed 6 months before the painless gastroscopy. 2. Complicated with severe liver dysfunction. 3. Poorly controlled or untreated hypertension (arterial hypertension, resting systolic/diastolic blood pressure over 180/100 mmHg), or prior severe angina attacks. 4. Patients with mental and nervous system diseases, cognitive and language disorders, unable to cooperate with postoperative follow-up or unable to express their feelings.

Design outcomes

Primary

Measure	Time frame
Pittsburgh Sleep Quality Index;	—

Countries

China

Contacts

Public ContactLeng Cuibo

Qingdao Central Medical Group

lengcuibo@163.com+86 17805325912

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026